# PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19

> **NCT04784767** · PHASE1 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 29 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
- **DRUG:** Sodium chloride, USP, for injection (0.9% NaCl)
- **BIOLOGICAL:** 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)

## Key facts

- **NCT ID:** NCT04784767
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-05
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-10-30
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-06-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04784767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04784767, "PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04784767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*